• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉内消融术治疗深静脉血栓形成病史患者的安全性和疗效。

Safety and efficacy of endovenous ablation in patients with a history of deep vein thrombosis.

机构信息

New York University Grossman School of Medicine, New York, NY.

Division of Vascular and Endovascular Surgery, Department of Surgery, New York University Langone Health, New York, NY.

出版信息

J Vasc Surg Venous Lymphat Disord. 2024 Sep;12(5):101898. doi: 10.1016/j.jvsv.2024.101898. Epub 2024 Apr 25.

DOI:10.1016/j.jvsv.2024.101898
PMID:38677553
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11523323/
Abstract

OBJECTIVE

Endovenous ablation is the standard of care for patients with symptomatic superficial venous insufficiency. For patients with a history of deep vein thrombosis (DVT), concern exists for an increased risk of postprocedural complications, particularly venous thromboembolism. The objective of this study was to evaluate the safety and efficacy of endovenous thermal ablation in patients with a history of DVT.

METHODS

The national Vascular Quality Initiative Varicose Vein Registry was queried for superficial venous procedures performed from January 2014 to July 2021. Limbs treated with radiofrequency or laser ablation were compared between patients with and without a DVT history. The primary safety end point was incident DVT or endothermal heat-induced thrombosis (EHIT) II-IV in the treated limb at <3 months of follow-up. The secondary safety end points included any proximal thrombus extension (ie, EHIT I-IV), major bleeding, hematoma, pulmonary embolism, and death due to the procedure. The primary efficacy end point was technical failure (ie, recanalization at <1 week of follow-up). Secondary efficacy end points included the risk of recanalization over time and the postprocedural change in quality-of-life measures. Outcomes stratified by preoperative use of anticoagulation (AC) were also compared among those with prior DVT.

RESULTS

Among 33,892 endovenous thermal ablations performed on 23,572 individual patients aged 13 to 90 years, 1698 patients (7.2%) had a history of DVT. Patients with prior DVT were older (P < .001), had a higher body mass index (P < .001), were more likely to be male at birth (P < .001) and Black/African American (P < .001), and had greater CEAP classifications (P < .001). A history of DVT conferred a higher risk of new DVT (1.4% vs 0.8%; P = .03), proximal thrombus extension (2.3% vs 1.6%; P = .045), and bleeding (0.2% vs 0.04%; P = .03). EHIT II-IV, pulmonary embolism, and hematoma risk did not differ by DVT history (P = NS). No deaths from treatment occurred in either group. Continuing preoperative AC in patients with prior DVT did not change the risk of any complications after endovenous ablation (P = NS) but did confer an increased hematoma risk among all endovenous thermal ablations and surgeries (P = .001). Technical failure was similar between groups (2.0% vs 1.2%; P = .07), although a history of DVT conferred an increased recanalization risk over time (hazard ratio, 1.90; 95% confidence interval, 1.46, 2.46; P < .001). The groups had comparable improvements in postprocedural venous clinical severity scores and Heaviness, Aching, Swelling, Throbbing, and Itching scores (P = NS).

CONCLUSIONS

Endovenous thermal ablation for patients with a history of DVT was effective. However, appropriate patient counseling regarding a heightened DVT risk, albeit still low, is critical. The decision to continue or withhold AC preoperatively should be tailored on a case-by-case basis.

摘要

目的

静脉内消融是有症状的浅静脉功能不全患者的标准治疗方法。对于有深静脉血栓形成(DVT)病史的患者,存在术后并发症风险增加的担忧,尤其是静脉血栓栓塞症。本研究的目的是评估静脉内热消融治疗有 DVT 病史患者的安全性和疗效。

方法

国家血管质量倡议静脉曲张登记处检索了 2014 年 1 月至 2021 年 7 月期间进行的浅静脉手术。比较了射频或激光消融治疗的肢体在有和无 DVT 病史的患者之间。主要安全性终点是治疗肢体在<3 个月随访时发生的新发 DVT 或热诱导血栓形成(EHIT)II-IV。次要安全性终点包括任何近端血栓延伸(即 EHIT I-IV)、大出血、血肿、肺栓塞和因手术导致的死亡。主要疗效终点是技术失败(即<1 周随访时再通)。次要疗效终点包括随时间推移再通的风险和术后生活质量测量的变化。还比较了术前使用抗凝剂(AC)的分层结果。

结果

在 23572 名年龄为 13 至 90 岁的个体中进行了 33892 次静脉内热消融治疗,其中 1698 名患者(7.2%)有 DVT 病史。有 DVT 病史的患者年龄较大(P<0.001)、体重指数较高(P<0.001)、更有可能在出生时为男性(P<0.001)和黑/非裔美国人(P<0.001),且 CEAP 分类更高(P<0.001)。DVT 病史使新发 DVT 的风险更高(1.4% vs 0.8%;P=0.03)、近端血栓延伸的风险更高(2.3% vs 1.6%;P=0.045)和出血风险更高(0.2% vs 0.04%;P=0.03)。EHIT II-IV、肺栓塞和血肿风险与 DVT 病史无关(P=NS)。两组均无治疗相关死亡。在有 DVT 病史的患者中继续术前 AC 并不会改变静脉内消融后的任何并发症风险(P=NS),但会增加所有静脉内热消融和手术的血肿风险(P=0.001)。两组之间的技术失败率相似(2.0% vs 1.2%;P=0.07),但 DVT 病史会增加随时间再通的风险(危险比,1.90;95%置信区间,1.46,2.46;P<0.001)。两组术后静脉临床严重程度评分和沉重感、疼痛、肿胀、悸动和瘙痒评分均有改善(P=NS)。

结论

对于有 DVT 病史的患者,静脉内热消融是有效的。然而,需要对患者进行适当的咨询,告知他们存在较高的 DVT 风险,尽管这种风险仍然较低。是否继续或停止术前 AC 应根据具体情况决定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b47/11523323/e1113dbbc20e/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b47/11523323/1d8e0845c61c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b47/11523323/6c40a1a1de20/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b47/11523323/96f5c0779366/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b47/11523323/e1113dbbc20e/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b47/11523323/1d8e0845c61c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b47/11523323/6c40a1a1de20/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b47/11523323/96f5c0779366/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5b47/11523323/e1113dbbc20e/fx1.jpg

相似文献

1
Safety and efficacy of endovenous ablation in patients with a history of deep vein thrombosis.静脉内消融术治疗深静脉血栓形成病史患者的安全性和疗效。
J Vasc Surg Venous Lymphat Disord. 2024 Sep;12(5):101898. doi: 10.1016/j.jvsv.2024.101898. Epub 2024 Apr 25.
2
Direct oral anticoagulant agents might be safe for patients undergoing endovenous radiofrequency and laser ablation.直接口服抗凝剂可能对接受静脉内射频和激光消融的患者安全。
J Vasc Surg Venous Lymphat Disord. 2023 Jan;11(1):25-30. doi: 10.1016/j.jvsv.2022.05.011. Epub 2022 Jul 21.
3
Outcomes of a single-center experience with classification and treatment of endothermal heat-induced thrombosis after endovenous ablation.单中心经验总结:腔内消融术后热诱导血栓形成的分类和治疗。
J Vasc Surg Venous Lymphat Disord. 2017 May;5(3):332-338. doi: 10.1016/j.jvsv.2016.12.010.
4
Safety and efficacy of endovenous ablations in octogenarians, nonagenarians, and centenarians.八十岁以上、九十岁以上和百岁以上老年人静脉内消融治疗的安全性和疗效。
J Vasc Surg Venous Lymphat Disord. 2020 Jan;8(1):95-99. doi: 10.1016/j.jvsv.2019.05.011. Epub 2019 Aug 27.
5
Resolution times of endovenous heat-induced thrombosis.静脉内热诱导血栓的分辨率时间。
J Vasc Surg Venous Lymphat Disord. 2020 Nov;8(6):1021-1024. doi: 10.1016/j.jvsv.2020.02.020. Epub 2020 Apr 19.
6
Effect of endovenous ablation assessment stratified by great saphenous vein size, gender, clinical severity, and patient-reported outcomes.静脉内消融评估的效果,按大隐静脉大小、性别、临床严重程度和患者报告的结果分层。
J Vasc Surg Venous Lymphat Disord. 2021 Jan;9(1):128-136. doi: 10.1016/j.jvsv.2020.04.017. Epub 2020 Apr 27.
7
Prospective randomized trial of antithrombotic strategies following great saphenous vein ablation using injectable polidocanol endovenous microfoam (Varithena).使用注射用聚多卡醇静脉微泡沫(Varithena)进行大隐静脉消融术后抗血栓形成策略的前瞻性随机试验
J Vasc Surg Venous Lymphat Disord. 2023 May;11(3):488-497.e4. doi: 10.1016/j.jvsv.2022.12.008. Epub 2022 Dec 31.
8
Rivaroxaban versus fondaparinux for thromboprophylaxis after endovenous laser ablation.利伐沙班与磺达肝癸钠预防静脉内激光消融术后血栓形成的比较。
J Vasc Surg Venous Lymphat Disord. 2017 Nov;5(6):817-823. doi: 10.1016/j.jvsv.2017.04.017. Epub 2017 Jun 26.
9
Radiofrequency and laser vein ablation for patients receiving warfarin anticoagulation is safe, effective, and durable.射频和激光静脉消融术用于正在接受华法林抗凝治疗的患者是安全、有效且持久的。
J Vasc Surg Venous Lymphat Disord. 2020 Jul;8(4):610-616. doi: 10.1016/j.jvsv.2019.11.013. Epub 2020 Jan 25.
10
Mechanochemical Endovenous Ablation of the Saphenous Vein: A Look at Contemporary Outcomes.静脉腔内机械化学消融治疗大隐静脉:当代结局观察。
Ann Vasc Surg. 2022 May;82:7-12. doi: 10.1016/j.avsg.2021.11.019. Epub 2021 Dec 18.

本文引用的文献

1
Endovenous laser ablation versus conventional surgery (ligation and stripping) for primary great saphenous varicose vein: a systematic review and meta-analysis.原发性大隐静脉曲张的腔内激光消融术与传统手术(结扎和剥脱术)的系统评价和荟萃分析
Ann Med Surg (Lond). 2023 Jul 25;85(9):4509-4519. doi: 10.1097/MS9.0000000000001095. eCollection 2023 Sep.
2
The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine.2023 年血管外科学会、美国静脉论坛和美国静脉与淋巴学会下肢静脉曲张管理临床实践指南。第二部分:得到介入放射学学会和血管医学学会的认可。
J Vasc Surg Venous Lymphat Disord. 2024 Jan;12(1):101670. doi: 10.1016/j.jvsv.2023.08.011. Epub 2023 Aug 29.
3
Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases.编辑推荐——欧洲血管外科学会(ESVS)2023年血管疾病抗栓治疗临床实践指南
Eur J Vasc Endovasc Surg. 2023 May;65(5):627-689. doi: 10.1016/j.ejvs.2023.03.042. Epub 2023 Apr 3.
4
Incidence and Significance of Deep Venous Reflux in Patients Treated with Saphenous Vein Ablation.大隐静脉消融治疗患者深静脉反流的发生率及意义
Ann Vasc Surg. 2023 Apr;91:182-190. doi: 10.1016/j.avsg.2022.11.034. Epub 2023 Jan 21.
5
Superficial venous procedures can be performed safely and effectively in patients with deep venous reflux.对于存在深静脉反流的患者,浅表静脉手术可以安全有效地进行。
J Vasc Surg Venous Lymphat Disord. 2023 Mar;11(2):281-292.e1. doi: 10.1016/j.jvsv.2022.09.017. Epub 2022 Nov 8.
6
A systematic review of routine post operative screening duplex ultrasound after thermal and non-thermal endovenous ablation.热和非热静脉内消融术后常规术后筛查双功能超声的系统评价。
J Vasc Surg Venous Lymphat Disord. 2023 Jan;11(1):193-200.e6. doi: 10.1016/j.jvsv.2022.06.006. Epub 2022 Aug 6.
7
Direct oral anticoagulant agents might be safe for patients undergoing endovenous radiofrequency and laser ablation.直接口服抗凝剂可能对接受静脉内射频和激光消融的患者安全。
J Vasc Surg Venous Lymphat Disord. 2023 Jan;11(1):25-30. doi: 10.1016/j.jvsv.2022.05.011. Epub 2022 Jul 21.
8
Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs.编辑推荐——欧洲血管外科学会(ESVS)2022年下肢慢性静脉疾病管理临床实践指南
Eur J Vasc Endovasc Surg. 2022 Feb;63(2):184-267. doi: 10.1016/j.ejvs.2021.12.024. Epub 2022 Jan 11.
9
Risk factors for short and long-term great saphenous vein recanalization in patients treated with endovenous radiofrequency ablation.射频消融治疗后大隐静脉近期和远期再通的危险因素。
Vascular. 2023 Feb;31(1):131-141. doi: 10.1177/17085381211058587. Epub 2021 Dec 15.
10
Risk factors for saphenous vein recanalization after endovenous radiofrequency ablation.腔内射频消融术后大隐静脉再通的危险因素。
J Cardiovasc Surg (Torino). 2021 Oct;62(5):427-434. doi: 10.23736/S0021-9509.21.11908-1. Epub 2021 May 20.